Bevacizumab for Retinopathy of Prematurity: Treatment When Pathology Is Embedded in a Normally Developing Vascular System

Affiliations

Editorial

William V Good. Ophthalmology. 2016 Sep.

. 2016 Sep;123(9):1843-4.

doi: 10.1016/j.ophtha.2016.06.054.

No abstract available

Comment in

Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology. 2016;123:1843-1844).
Blair MP, Shapiro MJ; Ad Hoc Group Concerning Neurodevelopment and antiVEGF. Blair MP, et al. Ophthalmology. 2017 Oct;124(10):e74-e75. doi: 10.1016/j.ophtha.2017.05.007. Ophthalmology. 2017. PMID: 28938930 No abstract available.
Reply.
Good WV. Good WV. Ophthalmology. 2017 Oct;124(10):e75. doi: 10.1016/j.ophtha.2017.05.001. Ophthalmology. 2017. PMID: 28938932 No abstract available.

Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.
Mintz-Hittner HA, Geloneck MM, Chuang AZ. Mintz-Hittner HA, et al. Ophthalmology. 2016 Sep;123(9):1845-55. doi: 10.1016/j.ophtha.2016.04.028. Epub 2016 May 27. Ophthalmology. 2016. PMID: 27241619 Free PMC article.